| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | 0.93 | 4e-06 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 7e-05 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.18 | 0.0001 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.099 | 0.001 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.16 | 0.003 |